. 2020 Aug 12;9(9):864–873. doi: 10.1530/EC-20-0292
This work is licensed under a Table 3.
Comparison between progressive disease and controlled disease.
| Parameters | Progressive disease (PD) | Controlled disease (PR + SD + MR) | P-value (95% CI) |
|---|---|---|---|
| Mean age (years) | 36.6 ± 22.5 | 42 ± 10.8 | 0.544 |
| Tumor type | PCC: 3 | PCC (1), sPGL(4), HNPGL(5), sPGL + HNPGL: 1, sPGL + PCC: 1 |
0.004a |
| Hypertension, n (%) | 3 (100) | 7 (58.3) | 0.20 |
| Pre-therapy PFNMN (mean ± s.d.) | 749 ± 1097 |
1321 ± 1369 | 0.93 |
| Change in DDD (%), n = 3 + 7 (mean ± s.d.) |
+207 ± 132 | −50.2 ± 43.6 | 0.001a |
| Change in PFNMN (mean ±s.d.) | +673 ± 597 | −11.1 ± 31.4 | 0.000a |
| No of PRRT cycle ( mean ± s.d.) | 3.5 ± 2.08 | 4.1 ± 1.8 | 0.63 |
| Mean dose of Lu (GBq) ( mean ± s.d.) | 23.6 ± 14.4 | 26.2 ± 1.9 | 0.49 |
| Pre-therapy 68Ga-DOTATATE SUVmax (mean), n = 13 (mean ± s.d.) |
12.4 ± 6.0 | 72.4 ± 70.9 | 0.18 |
| Baseline SUVmax>21, n = 14, n (%) | 0 (n = 3) | 90 (9/10) | 0.004a |
| Baseline mean (T/L) ( mean ± s.d.) | 1.2 ± 0.6 | 9.1 ± 9.4 | 0.18 |
| Baseline mean (T/S) (mean ± s.d.) | 0.49 ± 0.28 | 3.3 ± 4.2 | 0.28 |
| Reduction of mean SUVmax (tumor) more than 15% (n = 13) | 0/3 (0) | 8/10 (80) | 0.022a |
| Reduction mean SUVmax (T/L) > 15%, n (%) | 0/3 (0) | 5/8 (63) | 0.07 |
| Reduction mean SUVmax (T/S) > 15%, n (%) | 2/3 (33) | 4/8 (50) | 0.63 |
aP-value <0.05.
DDD, defined daily dose; HNPGL, head and neck paraganglioma; MR, minor response; PCC, pheochromocytoma; PD, progressive disease; PFNMN, plasma-free normetanephrine; PR, partial response; SD, stable disease; sPGL, sympathetic paraganglioma; SUVmax, standard uptake value maximum; T/L, tumor/liver; T/S, tumor/spleen.